Screener
Tango Therapeutics TNGX TNG260Direct Program Expenses-RD — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Oncology Segment / Three Months Ended March 31, 2026 | Oncology Segment / Three Months Ended March 31, 2025 |
|---|---|---|
| Less: | ||
| vopimetostat direct program expenses - R&D | 9,332 | 5,461 |
| TNG456 direct program expenses - R&D | 2,063 | 1,324 |
| TNG260 direct program expenses - R&D | 2,009 | 1,730 |
| TNG961 direct program expenses - R&D | 408 | 2,221 |
| TNG908 direct program expenses* - R&D | 581 | 1,712 |
| Discovery direct program expenses - R&D | 1,872 | 4,679 |
| Personnel-related expenses - R&D | 12,931 | 13,850 |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's tng260direct program expenses-rd — research and development expense?
- Tango Therapeutics (TNGX) reported tng260direct program expenses-rd — research and development expense of $2.01M in Q1 2026.
- How has Tango Therapeutics's tng260direct program expenses-rd — research and development expense changed year-over-year?
- Tango Therapeutics's tng260direct program expenses-rd — research and development expense increased by 16.1% year-over-year, from $1.73M to $2.01M.
- What is the long-term trend for Tango Therapeutics's tng260direct program expenses-rd — research and development expense?
- Over 3 years (2022 to 2025), Tango Therapeutics's tng260direct program expenses-rd — research and development expense has grown at a 8.6% compound annual growth rate (CAGR), from $4.91M to $6.28M.
- What does tng260direct program expenses-rd — research and development expense mean?
- This metric represents the direct research and development expenditures specifically allocated to the TNG260 clinical or preclinical program. It captures the costs associated with drug discovery, laboratory testing, and clinical trial activities required to advance this specific oncology asset through the development pipeline. Tracking these costs allows investors to assess the capital intensity and resource prioritization of a single therapeutic candidate within the company's broader precision medicine portfolio.
Ask your AI about Tango Therapeutics's tng260direct program expenses-rd — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude